Decline in U.S. Sales of Ag Tractors & Combines in June 2024

Jul 18, 2024

U.S. sales of Ag tractors and combines in June 2024 fell below reported sales from the same month a year ago, according to new data from the Association of Equipment Manufacturers (AEM).

June sales of 2-wheel-drive tractors dropped 16.3% compared to 2023, while 4-wheel-drive tractors fell 1.3% within the same timeframe. Combines sales declined as well, finishing the month 31% below June 2023.“June’s sales of Ag tractors and combines follow a May that also showed a slowdown in sales,” said AEM Senior Vice President Curt Blades. “This softness in the market follows a robust five years of sales. The challenges facing the subcompact tractor market illustrate why the passage of a strong farm bill is so needed to lift rural Americaand our farmers and growers.”

In Canada, sales of 4-wheel-drive tractors were a bright spot, growing 10.6% in June 2024 compared to the prior year. Canadian sales of combines increased year-to-date, finishing the month up 13.6%.

The Ag Tractor and Combine reports can be found on the AEM Market Share Statistics page. The U.S. report can be downloaded from this page, while the Canadian report is available for download here

Source : Farm Equipment

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.